Sarepta (SRPT) director sells 7,239 shares to cover RSU tax bill

Rhea-AI Filing Summary

Sarepta Therapeutics director Stephen Mayo reported an open-market sale of 7,239 shares of common stock at $17.02 per share. According to the footnote, this sale was made to generate cash to pay taxes arising from the vesting of restricted stock unit awards, indicating a tax-driven transaction rather than a discretionary portfolio move. After the sale, Mayo directly held 1,765 Sarepta shares.

Insights

Equity compensation and insider-transactions analyst

Director’s sale is primarily tax-related and relatively small in scale.

The Form 4 shows director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics common stock at $17.02 per share. The footnote explains the sale was to raise cash for taxes triggered by vesting restricted stock units, a common equity-compensation event.

Because the purpose is tax payment rather than a discretionary trade, the signal about Mayo’s view of Sarepta’s prospects is weak. Following the sale, he directly holds 1,765 shares, so the transaction meaningfully reduces his position but remains modest in absolute terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mayo Stephen

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S		7,239(1)	D	$17.02	1,765	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Stephen Mayo	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sarepta Therapeutics (SRPT) director Stephen Mayo report in this Form 4?

Stephen Mayo reported selling 7,239 shares of Sarepta Therapeutics common stock at $17.02 per share. The filing notes the sale was executed to generate cash to pay taxes owed from the vesting of restricted stock unit awards, indicating a compensation-related transaction.

Was the Sarepta Therapeutics (SRPT) insider stock sale a discretionary trade?

The filing states the 7,239-share sale was done to generate cash for taxes due from restricted stock unit vesting. That language shows the transaction was primarily tax-driven, rather than a purely discretionary decision to change exposure to Sarepta Therapeutics stock.

How many Sarepta Therapeutics (SRPT) shares did Stephen Mayo sell and at what price?

Stephen Mayo sold 7,239 shares of Sarepta Therapeutics common stock at an average price of $17.02 per share. This open-market transaction is recorded as a sale code "S" and is linked to tax obligations from equity compensation vesting, according to the footnote.

How many Sarepta Therapeutics (SRPT) shares does Stephen Mayo hold after the reported sale?

After the reported sale, Stephen Mayo directly holds 1,765 shares of Sarepta Therapeutics common stock. This figure, disclosed in the Form 4, reflects his remaining direct ownership following the 7,239-share open-market sale tied to tax obligations from restricted stock unit vesting.

What does the Form 4 footnote say about Stephen Mayo’s Sarepta (SRPT) stock sale?

The footnote explains that the reported sale represents shares sold to generate cash for paying taxes due from the vesting of certain restricted stock unit awards. This clarifies that the transaction is related to equity-compensation tax obligations rather than an ordinary portfolio reallocation.